2.4.2.29: tRNA-guanosine34 preQ1 transglycosylase
This is an abbreviated version!
For detailed information about tRNA-guanosine34 preQ1 transglycosylase, go to the full flat file.
Word Map on EC 2.4.2.29
-
2.4.2.29
-
anticodon
-
queuosine
-
wobble
-
mobilis
-
trnatyr
-
shigella
-
zymomonas
-
hypermodified
-
archaeosine
-
shigellosis
-
preq0
-
trna-modifying
-
trnaasn
-
trnahis
-
7-cyano-7-deazaguanine
-
minihelix
-
7-deazaguanosine
-
garcia
-
medicine
- 2.4.2.29
-
anticodon
-
queuosine
-
wobble
- mobilis
- trnatyr
- shigella
-
zymomonas
-
hypermodified
-
archaeosine
- shigellosis
- preq0
-
trna-modifying
- trnaasn
- trnahis
- 7-cyano-7-deazaguanine
- minihelix
- 7-deazaguanosine
- garcia
- medicine
Reaction
Synonyms
ArcTGT, guanine insertion enzyme, guanine, queuine-tRNA transglycosylase, Q-insertase, QTRT1, QueTGT, queuine insertase, queuine tRNA ribosyltransferase, queuine tRNA-ribosyltransferase, queuine tRNA-ribosyltransferase subunit 1, ribosyltransferase, queuine transfer ribonucleate, TGT, transfer ribonucleate glycosyltransferase, tRNA guanine transglycosidase, tRNA guanine transglycosylase, tRNA transglycosylase, tRNA-guanine 34 transglycosylase, tRNA-guanine transglycosylase, tRNA–guanine transglycosylase, virulence-associated protein VACC
ECTree
Advanced search results
Inhibitors
Inhibitors on EC 2.4.2.29 - tRNA-guanosine34 preQ1 transglycosylase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
2,6-bis(methylamino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
2-(methylamino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
2-([2-(morpholin-4-yl)ethyl]amino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
2-amino-5-(fluoromethyl)pyrrolo[2,3-d]pyrimidin-4(3H)-one
-
inactivation and competitive inhibition. 2-amino-5-(fluoromethyl)pyrrolo[2,3-d]pyrimidin-4(3H)-one appears to partition between: 1. normal turnover, 2. inactivation, 3. an alternative processing to an unidentrified fluoride-released product
2-[(2-phenylethyl)amino]-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
2-[(thiophen-2-ylmethyl)amino]-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
4-(2-[(cyclohexylmethyl)amino]ethyl)2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
4-(2-[(cyclopentylmethyl)amino]ethyl)-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
5-amino-3-(5-amino-1H-[1,2,4]triazol-3-yl-sulfanyl)-phthalhydrazide
-
6-(ethylamino)-2-(methylamino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
6-amino-2-(benzylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
6-amino-2-(methylamino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
6-amino-2-(methylamino)-3-[(methylamino)methyl]-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
6-amino-2-(methylamino)-3-[2-(methylamino)ethyl]-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
6-amino-2-(methylamino)-4-(2-[(1-naphthylmethyl)amino]ethyl)-1,7-dihydro-8Himidazo[4,5-g]quinazolin-8-one
-
6-amino-2-(methylamino)-4-(4-phenylbutyl)-1,7-dihydro-8H-imidazo-[4,5-g]quinazolin-8-one
-
6-amino-2-(methylamino)-4-[(methylamino)methyl]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
6-amino-2-(methylamino)-4-[2-(methylamino)ethyl]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
6-amino-2-([2-(morpholin-4-yl)ethyl]amino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
6-amino-2-[(1,3-benzodioxol-5-ylmethyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
6-amino-2-[(2-phenylethyl)amino]-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
6-amino-2-[(3-piperidin-1-ylpropyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
cannot modify the structure of the dimer interface, prevents the formation of the catalytically active Tgt:tRNA complex, and can disrupt the preformed complex
6-amino-2-[(4-morpholin-4-ylbenzyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
6-amino-2-[(quinolin-4-ylmethyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
6-amino-2-[(thiophen-2-ylmethyl)amino]-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
6-amino-4-(2-aminoethyl)-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
6-amino-4-(2-hydroxyethyl)-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
6-amino-4-(2-[(cycloheptylmethyl)amino]ethyl)-2-(methylamino)-1,7-dihydro-8Himidazo[4,5-g]quinazolin-8-one
-
6-amino-4-(2-[(cyclohexylmethyl)amino]ethyl)-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
6-amino-4-(2-[(cyclopentylmethyl)amino]ethyl)-2-(methylamino)-1,7-dihydro-8Himidazo[4,5-g]quinazolin-8-one
strongest inhibitor
6-amino-4-[2-(benzylamino)ethyl]-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
6-amino-4-[2-(methoxyphenyl)ethyl]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-4-[2-[(cyclohexylmethyl)amino]ethyl]-2-(methylamino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
6-amino-4-[2-[(cyclohexylmethyl)amino]ethyl]-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
can modify the structure of the dimer interface, prevents the formation of the catalytically active Tgt:tRNA complex, and can disrupt the preformed complex
6-amino-4-[2-[(cyclopentylmethyl)amino]ethyl]-2-(methylamino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
6-amino-4-[2-[(cyclopentylmethyl)amino]ethyl]-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
addresses a hydrophobic subpocket close to the dimer interface that may affect quarternary structure formation, prevents the formation of the catalytically active Tgt:tRNA complex, and can disrupt the preformed complex
methyl 1-[(dimethylamino)sulfonyl]-2-(methylamino)-5-nitro-1H-benz-imidazol-6-carboxylate
-
methyl 5-amino-1-[(dimethylamino)sulfonyl]-2-(methylamino)-1H-benz-imidazol-6-carboxylate
-
methyl 5-amino-1-[(dimethylamino)sulfonyl]-2-(methylamino)-4-(4-phenyl-1-butyn-1-yl)-1H-benzimidazole-6-carboxylate
-
methyl 5-amino-1-[(dimethylamino)sulfonyl]-2-(methylamino)-4-(4-phenylbutyl)-1Hbenzimidazole-6-carboxylate
-
methyl 5-amino-1-[(dimethylamino)sulfonyl]-2-(methylamino)-4-vinyl-1H-benzimidazole-6-carboxylate
-
methyl 5-amino-1-[(dimethylamino)sulfonyl]-2-(methylamino)-4-[2-(methylamino)ethyl]-1H-benzimidazole-6-carboxylate
-
methyl 5-amino-1-[(dimethylamino)sulfonyl]-2-(methylamino)-4-{2-[(1-naphthylmethyl)amino]ethyl}-1H-benzimidazole-6-carboxylate
-
methyl 5-amino-1-[(dimethylamino)sulfonyl]-4-(2-hydroxyethyl)-2-(methylamino)-1H-benzimidazole-6-carboxylate
-
methyl 5-amino-1-[(dimethylamino)sulfonyl]-4-iodo-2-(methylamino)-1H-benzimidazole-6-carboxylate
-
methyl 5-amino-1-[(dimethylamino)sulfonyl]-4-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-2-(methylamino)-1H-benzimidazole-6-carboxylate
-
methyl 5-amino-4-(2-aminoethyl)-1-[(dimethylamino)sulfonyl]-2-(methylamino)-1H-benzimidazole-6-carboxylate
-
methyl 5-amino-4-(2-[(cycloheptylmethyl)amino]ethyl)-1-[(dimethyl-amino)sulfonyl]-2-(methylamino)-1H-benzimidazole-6-carboxylate
-
methyl 5-amino-4-(2-[(cyclohexylmethyl)amino]ethyl)-1-[(dimethylamino)sulfonyl]-2-(methylamino)-1H-benzimidazole-6-carboxylate
-
methyl 5-amino-4-(2-[(cyclopentylmethyl)amino]ethyl)-1-[(dimethylamino)sulfonyl]-2-(methylamino)-1H-benzimidazole-6-carboxylate
-
methyl 5-amino-4-(2-[benzyl(methyl)amino]ethyl)-1-[(dimethylamino)sulfonyl]-2-(methylamino)-1H-benzimidazole-6-carboxylate
-
methyl 5-amino-4-[2-(benzylamino)ethyl]-1-[(dimethylamino)sulfonyl]-2-(methylamino)-1H-benzimidazole-6-carboxylate
-
methyl 5-amino-4-{2-[(cyclohexylcarbonyl)amino]ethyl}-1-[(dimethylamino)sulfonyl]-2-(methylamino)-1H-benzimidazole-6-carboxylate
-
methyl 8-benzyl-3-[(dimethylamino)sulfonyl]-2-(methylamino)-3,6,7,8,9,10-hexahydroimidazo[4,5-g][1,3]benzodiazepine-5-carboxylate
-
N-(2-[6-amino-2-(methylamino)-8-oxo-7,8-dihydro-1H-imidazo[4,5-g]quinazolin-4-yl]ethyl)cyclohexanecarboxamide
-
additional information
-
design, synthesis, and in vitro evaluation of novel tricyclic TGT inhibitors based on the lin-benzoguanine scaffold
-
-
6-amino-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-2-[(2-morpholin-4-ylethyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-2-[(2-phenylethyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-2-[(naphthalen-1-ylmethyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-2-[(thiophen-2-ylmethyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
-
6-amino-3-(2-phenylethyl)-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
-
6-amino-4-(2-phenylethyl)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-4-[2-(4-methoxyphenyl)ethyl]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
can modify the structure of the dimer interface, prevents the formation of the catalytically active Tgt:tRNA complex, and can disrupt the preformed complex
-
-
6-amino-4-[2-(4-methylphenyl)ethyl]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-4-[2-(benzylamino)ethyl]-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
addresses a hydrophobic subpocket close to the dimer interface that may affect quarternary structure formation, prevents the formation of the catalytically active Tgt:tRNA complex, and can disrupt the preformed complex
mixed competitive-uncompetitive inhibition with respect to tRNA binding